Duncan H. Mak - Concepedia

Author

Duncan H. Mak

The University of Texas MD Anderson Cancer Center

Also Known As

D H Mak, D Mak, D. H. F. Mak, D. H. Mak, D. Mak, D.H.F. Mak, Dominic Mak, Duncan H Mak, Duncan H. F. Mak, Duncan H. Mak

169

Publications

3.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Hong Kong University of Science and Technology University of Hong Kong

About

Duncan H. Mak is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	1.2K
2	Cell Biology	14	16	803
3	Health Sciences	4	4	179
4	Biochemistry	2	2	194
5	Cellular Physiology	2	2	65

Duncan H. Mak

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells May Daher, Rafet Başar, Elif Gokdemir, Blood	2020	272
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells Bing Z. Carter, Duncan H. Mak, Wendy Schober, Blood	2006	202
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells Bing Z. Carter, Po Yee Mak, Hong Mu, Science Translational Medicine	2016	168
Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5 Bing Z. Carter, Duncan H. Mak, Wendy Schober, Blood	2008	136
RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex Marina Konopleva, Michèle Milella, Peter P. Ruvolo, Leukemia Hematological MalignancyCancer ResearchReceptor Tyrosine KinaseApoptosisCell Death	2011	136
Phase I/II Trial of AEG35156 X-Linked Inhibitor of Apoptosis Protein Antisense Oligonucleotide Combined With Idarubicin and Cytarabine in Patients With Relapsed or Primary Refractory Acute Myeloid Leukemia Aaron D. Schimmer, Elihu H. Estey, Gautam Borthakur, Journal of Clinical Oncology	2009	121
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition Bing Z. Carter, Po Yee Mak, Wenjing Tao, Haematologica Mixed-phenotype Acute LeukemiaCell DeathCancer BiologyTumor BiologyMyeloid Neoplasia	2020	118
<i>In Vivo</i>Antioxidant Action of a Lignan-Enriched Extract of<i>Schisandra</i>Fruit and an Anthraquinone-Containing Extract of<i>Polygonum</i>Root in Comparison with Schisandrin B and Emodin Po-Yee Chiu, Duncan H. Mak, Michel K.T. Poon, Planta Medica Lipid PeroxidationPme/emodin PretreatmentLignan-enriched ExtractAnthraquinone-containing ExtractPolyphenolics	2002	114
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models Lina Han, Qi Zhang, Monique Dail, Haematologica	2019	111
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells Bing Z. Carter, Duncan H. Mak, Wendy Schober, Blood	2005	101

Page 1